Title page

1

5

12

14

17

22

33

- 2 Full title: A Bibliometric Analysis of Research Hotspots and Frontiers in Diabetes and
- 3 Cardiovascular Disease Comorbidity from 2005 to 2024
- 4 **Authors list:** Jingjin Wang^{1a}, Tianyuan Su^{#1b}, Yunlong Li^{2a}, Yinxia SU^{c*}, Yukai Li^{d*}
- From the School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China 6
- 7 ^bTelemedicine Center of The First Affiliated Hospital Xinjiang Medical University, Urumqi,
- 8 Xinjiang, China.
- 9 c*School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi,
- 10 Xinjiang, China.
- 11 d*Yili Normal University, Yi ning, Xinjiang, China.
- 13 *These authors contributed engally, and thus they were joint-first authors.
- 15 Jingjin Wang, Yinxia SU and Yukai Li takes responsibility for all aspects of the reliability and
- 16 freedom from bias of the data presented and their discussed interpretation.
- *Corresponding author: Yinxia Su, 567 Shangde North Road, Shuimogou District, Urumqi City, 18
- 19 *Xinjiang 830000, China Tel:* +86 15022971910; E-mail: yinxia su@xjmu.edu.cn
- 20 Yukai Li, 393 Xinyi Road, Xinshi District, Urumqi City, Xinjiang 830000, China Tel: +86
- 21 13999266994; E-mail: XjLyk11@tomm.com
- 23 E-mail address of all authors:
- 24 JW:1099337027@qq.com;
- 25 TS:644580772@qq.com;
- 26 Yl:16699195071@stu.xjmu.edu.cn;
- 27 YS:yinxia su@xjmu.edu.cn;
- 28 YL:XjLyk11@tomm.com.

Funding 29

- 30 This work was supported by the Special Project for Innovation Environment (Talent, Base)
- Construction in Xinjiang Uygur Autonomous Region and the HeTian Prefecture Science and 31
- 32 Technology Research and Development Program Project (NO.2022D01A256 and NO.202314).

34 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Abstract: Nearly two decades ago, diabetes mellitus (DM) and cardiovascular disease (CVD) emerged as major global health threats, with research interest steadily increasing. Despite ongoing in-depth studies in the DM+CVD field, a systematic analysis of overall development trends and future hotspots remains lacking. This study employs bibliometric methods, utilizing CiteSpace and VOSviewer software to analyze and visualize 5,505 DM+CVD-related publications from 2005 to May 2024. The findings reveal a rapid growth trend in the field, with publications peaking at 751 in 2022, and the United States and China as major contributing countries. Keyword analysis identifies research hotspots including oxidative stress, insulin resistance, and heart failure. Highly cited literature analysis shows that the relationship between DM+CVD and obesity, disease mechanisms, treatment strategies, lifestyle interventions, and novel drugs are primary research themes. Analysis of highly cited literature from the past three years indicates that the application of SGLT2 inhibitors and GLP-1 receptor agonists, the association between metabolic abnormalities and DM+CVD, precise management of heart failure and cardiomyopathy, and in-depth epidemiological studies are current and future research priorities. This study not only reveals research hotspots and development trends in the DM+CVD field but also provides important references for optimizing research resource allocation and promoting multidisciplinary collaboration. Keywords: Diabetes Mellitus; Cardiovascular Diseases; Hotspots and Frontiers; Bibliometrics; Research Trends.

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Diabetes Mellitus (DM) is a group of chronic metabolic disorders characterized by hyperglycemia, primarily resulting from defects in insulin secretion or its biological action, with the potential for chronic damage and dysfunction of multiple organs¹. DM is broadly classified into Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), and Gestational Diabetes Mellitus (GDM). T1DM is an autoimmune disease, generally attributed to the abnormal activation of immune cells, such as CD8+ T and CD4+ T cells, which target and attack the body's pancreatic β-cells². T2DM, accounting for 90-95% of all DM cases, is primarily characterized by insulin resistance and relative insulin deficiency, typically associated with genetic predisposition, lifestyle factors, and environmental influences^{2,3}. GDM refers to any degree of glucose intolerance first appearing or detected during pregnancy, potentially affecting maternal and fetal health4. Although GDM typically resolves postpartum, some women may continue to exhibit glucose metabolism abnormalities and face an increased risk of developing T2DM in the future^{2,4}.Currently, the global prevalence of DM is increasing significantly, driven by demographic shifts and lifestyle changes. According to the International Diabetes Federation (IDF)⁵, the number of adults with DM reached 537 million in 2021, with projections estimating an increase to 783 million by 2045. This trend not only imposes a substantial economic burden but also significantly impacts societal development. In 2021, global healthcare expenditure attributed to DM was estimated at 966.6 billion USD, representing an approximate 43% increase from 20155. In the United States alone, the total cost associated with DM in 2022 was approximately 412.9 billion USD, comprising 306.6 billion USD in direct medical costs and 106.3 billion USD in indirect costs. These indirect costs encompass reduced employment rates, decreased work

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

attendance, and premature mortality due to DM, collectively resulting in a productivity loss of 96.5 billion USD⁶. Cardiovascular Diseases (CVD) are one of the primary causes of death among patients with DM^{7,8}, while DM is also a major risk factor for CVD⁹. According to a report by the American Heart Association (AHA)¹⁰, at least 68% of DM patients aged 65 or older die from some form of CVD; in China, the proportion of T2DM patients who die from CVD is even higher, reaching 75%¹¹. The chronic hyperglycemic state in DM patients leads to a series of pathological changes, such as endothelial cell dysfunction and vascular smooth muscle cell proliferation, which increase the risk of cardiovascular disease^{7,12}. Furthermore, DM patients often present with a cluster distribution of risk factors, including hypertension, obesity, and dyslipidemia², which further increases cardiovascular risk. Epidemiological studies indicate that, compared to non-DM populations, DM patients have a 5 to 15 percentage point higher risk of major cardiovascular events such as coronary heart disease¹³. Despite the extensive research in the field of DM+CVD, systematic analyses of its research hotspots and frontiers remain relatively scarce. Given the profound impact of DM+CVD on patient health and socioeconomic conditions¹⁴, a comprehensive understanding of the research dynamics in this field is of paramount importance. Therefore, this study aims to conduct a systematic analysis of the DM+CVD field using bibliometric methods, employing two literature visualization software tools: CiteSpace and VOSviewer. Compared to traditional systematic reviews, bibliometrics offers the advantage of summarizing research fields from a macro and comprehensive perspective, utilizing mathematical and statistical models for quantitative and

visual analysis of knowledge carriers^{15,16}. The CiteSpace and VOSviewer software tools selected

for this study each have their unique features: CiteSpace is renowned for its robust temporal perspective functionality and rich analytical indicators, while VOSviewer is known for its intuitive interface and high flexibility^{17,18}. By combining the strengths of these two software tools, we can scientifically identify active researchers, potential collaborators, popular topics, and future research frontiers in the field. Through this approach, we aim to provide a comprehensive reference of hotspots and frontiers in the DM+CVD field for relevant researchers, while also elucidating the research trajectory and evolutionary trends within this domain.

1. Materials and Methods

1.1.Data Source

The primary data source for this study was the Web of Science Core Collection (WOSCC) database, utilizing the SCI-Expanded index. To comprehensively cover DM+CVD-related research, we established the following search criteria: the search term combination was (TS=("diabetes" OR "diabetic") AND TS=("cardiovascular diseases" OR "cardiac diseases" OR "heart diseases"). Document types were restricted to "Article" and "Review Article", with all open access publications included. The language was limited to English, and the search timespan was set from January 1, 2005 to May 5, 2024. To explore the multifaceted impacts of DM+CVD in depth, we applied detailed restrictions to the citation topic Meso, encompassing but not limited to the following 34 fields (for a complete list, see Table S1): Diabetes, Phytochemicals, Lipids, Nutrition & Dietetics, and Cardiology - Circulation. Limiting these broad topic areas ensures that the research scope of DM+CVD is explored from multiple angles and levels. Through this multidisciplinary analytical approach, we can systematically evaluate research progress across various domains, from basic medicine to clinical practice, and from drug research to public health

policy, thereby forming a comprehensive and in-depth analytical framework. Finally, using the aforementioned search method, 5505 publications were retrieved, including 3781 articles and 1724 reviews. The full records and references were imported into CiteSpace and VOSviewer software for quantitative analysis.

1.2.Analytical Methods

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

This study utilized CiteSpace 6.3R1 and VOSviewer software for the visualization analysis of selected publications. In the data preprocessing phase, we imported bibliographic data into CiteSpace for duplicate screening, which yielded no duplicate entries. For CiteSpace parameter configuration, the time span was set from 2005 to 2024, with annual time slices. Term sources encompassed Title, Abstract, Author Keywords (DE), and Keywords Plus (ID) to comprehensively capture key information from the literature. We employed pathfinder and pruning sliced networks algorithms for network pruning to optimize visualization outcomes. The Selection Criteria was set to TOPN, utilizing the software's default threshold of 50, while maintaining other parameters at their default values. In VOSviewer, we flexibly adjusted thresholds for each node based on visualization requirements, with other parameters adhering to default settings. For analytical dimensions, we selected authors, publishing institutions, countries/regions, keywords, and references as primary analytical foci to comprehensively grasp collaboration patterns and knowledge structures within the field. In terms of visualization mapping, we generated collaboration network diagrams, co-occurrence network diagrams of cited literature, and co-citation network diagrams of cited literature using CiteSpace and VOSviewer to visually represent their characteristics and relationships. Additionally, Scimago Graphica was employed in conjunction with VOSviewer to provide a more intuitive display of collaboration

networks and research impact across countries/regions. To elucidate core research themes and their evolution, we utilized CiteSpace's keyword clustering functionality to conduct cluster analysis on key concepts in the research field, identifying primary research themes and corresponding concept clusters. Subsequently, we generated a Timeline-based Theme River diagram to visualize the developmental trajectories and historical evolution of different clusters. Furthermore, we constructed keyword density maps using VOSviewer to identify research hotspots and reveal the field's overall knowledge structure. To explore research frontiers and emerging trends, we analyzed highly cited literature and their keywords from the past three years using CiteSpace. Through keyword analysis functions, particularly the Spotlight algorithm, we uncovered the strength of associations between keywords. Concurrently, by employing the Burst Detection algorithm for in-depth analysis of highly cited literature from the past three years, we successfully captured rapidly emerging research hotspots. Moreover, we utilized Excel for processing and organizing raw data, and R (version 4.3.1) with ggplot2 and forecast packages, along with Excel, to generate supplementary statistical charts and graphs.

2. Analysis of Bibliometric Characteristics

2.1Publication Trends and Impact Analysis

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

From January 2005 to December 2023, the WOSCC indexed a total of 5404 articles in the field of DM+CVD, as illustrated in Figure 1. The number of publications related to DM+CVD research has demonstrated a consistent annual increase, with particularly significant increases observed during the period of 2019-2022. During this time, the annual publication volume increased substantially compared to the previous year, with an average growth rate of 21.85%. The peak in publication output was reached in 2022, with 751 articles published. Although the

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

data for 2023 indicates a slight decline, considering the overall trend and historical data, this may be interpreted as a short-term fluctuation based on the overall trend. It is noteworthy that at the time of this study's completion, publications for 2024 were still being continuously indexed. Given the non-linear growth characteristics of historical publication numbers, this study employed polynomial regression (second-order) to forecast the publication volume for 2024. Based on the predicted publication volume, it is estimated that 2024 will see approximately 812 publications, 95% CI [679, 946]. Judging from both the publication volume and short-term forecast results, it is evident that the attention and activity in the DM+CVD field continue to increase, garnering widespread interest from scholars. FIG 1. Annual publication volume in DM+CVD (2005-2024). The graph shows the annual number of publications in the field of diabetes mellitus and cardiovascular disease comorbidity (DM+CVD) from 2005 to 2023, with a forecast for 2024. Black points represent actual publication counts, while the black line shows the trend. The red point for 2024 indicates the forecasted value (812) based on polynomial regression. Equation of the regression line and statistical parameters (R², Adjusted R², p-value) are shown in the top left. The 95% confidence interval for the 2024 forecast (679-946) is displayed in the top right. Note: 2023 data may be incomplete due to ongoing indexing. The WOS citation report function indicates that the retrieved publications have accumulated a total of 272,346 citations, with an average of 49.47 citations per article. The H-index, which reflects the impact and reputation of relevant research, stands at 212 for publications in the DM+CVD field, demonstrating the significant academic influence and the depth and durability of research outcomes in this domain. The WOS journal analysis report function reveals that all

publications from 2005 to May 2024 originated from 118 journals. This study primarily analyzed the top 10 journals by publication volume, as shown in Table 1. Among these, PLoS ONE published the highest number of articles at 199, closely followed by the *International Journal of* Molecular Sciences with 159 publications. Cardiovascular Diabetology, Nutrients, and Circulation also maintained publication volumes exceeding 100 articles each. Notably, among the top 10 journals by publication volume, MDPI-affiliated journals account for over 30% of the publications, while BMC-affiliated journals follow closely, comprising 19% of the total. The Impact Factor (IF) is a crucial metric for assessing a journal's academic influence. Among the top 10 journals by publication volume, Circulation has the highest IF at 37.8, while Frontiers in Cardiovascular Medicine has the lowest at 3.6. The distribution of H-indices follows a similar pattern to IF, with Circulation having the highest H-index of 674 and Frontiers in Cardiovascular Medicine the lowest at 69.In summary, research in the DM+CVD field demonstrates a sustained growth trend and exerts a profound and significant influence in academia. The continued attention from high-quality journals and high citation rates reflect the importance and research value of this field.

2.2Collaboration Network Analysis

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

From 2005 to 2024, research in the DM+CVD field involved contributions from 159 countries/regions, 7,137 institutions, and 34,707 authors. As shown in Figure 2, international collaboration in this field exhibits distinct geographical distribution patterns. Figure 2(A) displays the top 25 countries ranked by collaboration intensity, with European countries being particularly densely represented, indicating active research cooperation in this region. Regarding inter-country collaborations, the connecting lines between the United States and China, as well as between the

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

United States and the United Kingdom, are particularly thick, reflecting close collaborative relationships among these countries. Figure 2(B) presents the top 10 countries/regions ranked by publication output. The United States leads with 1,257 publications, while China ranks second with 1,032 publications. Notably, there is a significant gap in publication numbers between the United Kingdom (ranked third) and subsequent countries compared to the United States and China. A comprehensive analysis of collaboration networks and publication data highlights the prominent positions of the United States and China in this research field, demonstrating their global academic influence and research capabilities. FIG 2. Map of countries/regions network cooperation (A) and top 10 countries/regions(B) in DM+CVD. (A) World map showing international collaboration networks. Lines represent collaborative links between countries, with different colors indicating distinct collaboration clusters. (B) Bar chart of the top 10 countries by publication count. The United States (1287 publications) and China (1032 publications) lead in research output, followed by the United Kingdom, Italy, and Japan. The institutional collaboration network is depicted in Figure 3. In Figure 3(A), node size represents each institution's publication output, while Figure 3(B) displays specific publication data. Harvard University tops the list with 226 publications, followed by Harvard Medical School (139) and University of London (134). Notably, 60% of the top 10 institutions by publication count are from the USA, highlighting the country's dominant position and substantial contributions in this research field. This phenomenon also reflects the research strength and innovative capacity of American academic institutions in this domain. FIG.3 Institutional Cooperation Network (A) and top 10 Affiliations(B) in DM+CVD.

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

(A) Visualization of institutional collaboration network. Nodes represent institutions, with size indicating publication volume. Colors denote different collaboration clusters. Lines represent collaborative links between institutions. (B) Bar chart showing top 10 institutions by publication count. Harvard University (USA) leads with 208 publications, followed by Harvard Medical School (USA) with 139 publications. Figure 4 illustrates the author collaboration network and the top 10 authors by publication count. The intensity of the connecting lines in the network reflects the closeness of collaboration among authors. The top 10 authors typically have dense connections with other researchers, indicating their key roles in the collaborative network. It is noteworthy that some Chinese scholars, including Yang Ling, Chen Junshi, and Guo Yu, also show dense interconnections, reflecting the active engagement of Chinese research teams in this field. Among the top 25 ranked authors, 24% are Swedish, 20% are American, while among Asian countries, Japanese scholars comprise the highest proportion at 12%, followed by Chinese scholars at 8%. This distribution further accentuates the leading position of European and American countries in this field, while also signifying the increasingly significant roles of Asian countries, particularly Japan and China. FIG.4 Author Cooperation Network (A) and top 10 Authors(B) in DM+CVD. (A) Visualization of author collaboration network. Nodes represent individual authors, with size indicating publication volume. Colors denote different collaboration clusters. Lines represent co-authorship links. (B) Bar chart showing top 10 authors by publication count. In conclusion, within the interdisciplinary field of DM+CVD research, the United States, China, and European countries demonstrate notably high contributions. The United States maintains a leading position in overall research output, while European countries exhibit a more densely interconnected collaboration network. Asian countries, particularly China and Japan, also showcase robust research capabilities. This diverse landscape of international collaboration not only promotes knowledge exchange and innovation but also lays a solid foundation for the global development of this field.

2.3 Keyword Analysis: Dynamics and Trends

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

Through an analysis of keywords from 5,505 publications in the DM+CVD field, we systematically identified the research hotspots and developmental trends in this domain. VOSviewer data revealed a total of 8,250 keywords, with 16 keywords occurring more than 100 times. The keyword co-occurrence, cluster analysis, density distribution, and keyword bursts are illustrated in Figure 5.In the keyword co-occurrence network (Figure 5A), node size reflects keyword frequency. Larger nodes for terms such as "cardiovascular disease," "diabetes mellitus," and "obesity" align with the VOSviewer statistical data (Figures 5C, 5D) and correspond to our research focus. Other prominent keywords include "insulin resistance," "hypertension," "metabolic syndrome," "inflammation," reflecting disease-related factors, risk factors, pathophysiological processes associated with DM+CVD from various perspectives. Keywords like "gene expression" and "oxidative stress" indicate researchers' interest in the fundamental mechanisms of DM+CVD. Terms such as "blood pressure" and "heart failure" highlight research hotspots in clinical manifestations and complications. Descriptive terms like "association" and "impact" correspond to scholars' diverse research interests in different aspects of DM+CVD, reflecting to some extent the multidimensionality and complexity of research in this field. To better understand the underlying logic behind the keywords, we conducted a cluster analysis, with results shown in Figure 5B. The clustering indicators yielded a Q value of 0.4358

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

and an S value of 0.7674. Generally, Q > 0.3 indicates significantly effective clustering, S > 0.5 suggests reasonable clustering, and S > 0.7 denotes convincing clustering results 17. The cluster analysis revealed the current research hotspots in DM+CVD:Clusters #0 (oxidative stress) and #1 (insulin resistance) indicate an in-depth exploration of fundamental pathological mechanisms. Clusters #2 (blood pressure), #3 (heart failure), and #4 (atrial fibrillation) reflect researchers' emphasis on common clinical manifestations in DM+CVD patients. Clusters #5 (impaired glucose tolerance) and #6 (type 2 diabetes) demonstrate research interest in the entire disease progression process. The emergence of cluster #7 (birth weight) suggests that research has extended to early life stages, exploring factors that may influence the development of DM+CVD in adulthood. Keyword burst analysis provides a crucial perspective for unveiling the dynamic evolution of the DM+CVD field. By identifying highly focused themes within specific periods, it offers insights into the shifts in research hotspots and helps capture emerging trends. Based on the keyword burst strength diagram generated by CiteSpace (Figure 5E), we conducted an in-depth analysis of the evolving research hotspots in the DM+CVD domain. The results indicate that C-reactive protein (CRP) exhibited the strongest burst strength (20.22) between 2005 and 2014, likely reflecting the intense research interest in inflammatory markers' role in DM+CVD during this period. This was closely followed by diabetic cardiomyopathy (20.01, 2021-2024) and follow-up (19.24, 2005-2014). Notably, diabetic cardiomyopathy, as a relatively new research hotspot, has a burst period overlapping with the current timeframe, suggesting it may be one of the focal points of recent studies. Further analysis revealed multiple keywords showing burst trends in the 2021-2024 period, including the aforementioned diabetic cardiomyopathy, epidemiology (18.54), mechanism (16.14), and heart failure (12.98). These concurrent bursts may reflect the

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

latest trends in DM+CVD research, namely an in-depth exploration of disease mechanisms, reassessment of epidemiological characteristics, and a focus on specific complications such as heart failure and diabetic cardiomyopathy. Additionally, we observed that certain keywords, such as "mechanism," although present in research as early as 2007, did not show a significant burst trend until 2022. This lag phenomenon may indicate a shift in research focus from phenomenon description to mechanism exploration, reflecting an increase in knowledge accumulation and research depth within the field. Simultaneously, we noted that some earlier hotspots, such as CRP and acute myocardial infarction (18.18, 2005-2012), have concluded their burst periods. This may suggest that related research has matured or that research priorities have shifted. FIG 5. Keyword co-occurrence (A), clustering (B), density map (C), top 20 keywords (D) and Top 25keywords bursts(E) in the field of DM+CVD (2005-2024). (A) Keyword co-occurrence network. Node size indicates keyword frequency; colors represent different clusters.(B) Clusters of major research topics. Colored clusters show the evolution of research themes over time.(C) Density visualization of keyword co-occurrence. Red areas indicate high-frequency keywords and their relationships.(D) Bar chart of top 20 keywords by frequency. 'Cardiovascular disease' and 'diabetes mellitus' are the most frequent terms.(E) Top 25 keywords with the strongest citation bursts, showing emergence years and burst durations. The analysis of keywords and their evolutionary trends reveals the diversity and progression of research hotspots in the field. There has been a notable shift from the early focus on inflammatory markers and acute cardiovascular events to a more in-depth exploration of specific complications, such as diabetic cardiomyopathy and heart failure. The recently emerging keywords indicate that current research is concentrating on a deeper understanding of disease mechanisms and a

reassessment of epidemiological characteristics. This progression demonstrates the continuous advancement of scientific knowledge in the DM+CVD field.

3. Analysis of Highly Cited Papers

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

Building upon our earlier keyword analysis that revealed research hotspots and trends in the DM+CVD field, we now turn our attention to the analysis of highly cited papers. These publications encapsulate the most significant scientific achievements in a discipline and represent the developmental level of the field. Analyzing highly cited papers allows for a comprehensive understanding of the structural framework and overall characteristics of the discipline. Figure 6 presents a dual-map overlay of research journals in the DM+CVD field, broadly illustrating two primary citation pathways. Published articles primarily fall within the domains of medicine, clinical research, molecular biology, and immunology, while cited literature predominantly originates from journals in health, nursing, medicine, molecular biology, and genomics. This reflects the interdisciplinary nature of research in this field and the balance between basic research and clinical applications. VOSviewer data indicate that 5,505 articles encompass 269,272 citations. As shown in Figure 7, there are 10 main clusters, including: #0 coronary disease, #1 treatment outcome, #2 heart failure, #3 myocardial infarction, #4 diabetes mellitus, #5 asymmetric dimethylarginine, #6 resveratrol, #7 epidemiology, #8 insulin resistance, #9 protein kinases, and #10 myocardial biology. These clusters reveal the core issues and research hotspots in the field. Through statistical and visual analysis of highly cited papers, combined with the citation report function of WOSCC, we discussed novel findings and key literature driving the development of the discipline, encompassing 28 articles and 22 reviews.

FIG 6. Dual-map overlay of the journals on DM+CVD research (2005-2024).Left side represents

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

citing journals, right side represents cited journals. Each colored cluster represents a distinct research field. Lines connect citing journals to cited journals, showing interdisciplinary knowledge flow. Thickness of lines indicates citation frequency. FIG 7. Co-citation network (A), top50 co-cited literature (B), and Timeline-based Theme River diagram (C) in DM+CVD(2005-2024). (A) Co-citation network of authors generated by CiteSpace. Node size represents citation frequency; colors indicate publication year (blue for older, red for more recent). (B) Co-citation network of literature generated by VOSviewer. Nodes represent publications; links indicate co-citation relationships. Different colors represent distinct clusters, each corresponding to a specific research theme or sub-field. (C) Landscape view of research topics from 2000 to 2023 created by CiteSpace. Each colored stream represents a major research theme, with labels indicating specific topics. The width of streams indicates the relative prominence of topics over time 3.1Review. Reviews not only help researchers gain a comprehensive understanding of existing research findings and developmental trends but also facilitate knowledge accumulation and dissemination while identifying and addressing key issues through expert perspectives. To ensure research quality, authority, and impact, we selected 22 highly cited reviews published in top-tier journals such as The Lancet, Circulation Research, Circulation, Endocrine Reviews, European Heart Journal, and Cell Metabolism for analysis. These reviews have been categorized by research topic and ordered chronologically to distill the core information of their content. Research on the Relationship Between Obesity and Disease In 2005, Daniels SR et

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

al. 19 reviewed the pathophysiological mechanisms of obesity in children and adolescents, elucidating how obesity leads to the development of DM band CVD through insulin resistance, chronic inflammation, and metabolic syndrome. This study not only provided crucial insights into understanding the pathogenesis of CVD in DM patients but also proposed multi-level prevention strategies encompassing lifestyle, family, community, and policy interventions, laying a theoretical foundation for subsequent research and policy formulation. In 2009, Daphne et al.²⁰ conducted a meta-analysis synthesizing data from 89 studies. Their findings demonstrated a significant correlation between overweight/obesity and the risk of various chronic non-communicable diseases, particularly T2DM and CVD. By integrating extensive epidemiological data, this study provided robust evidence for understanding the association between overweight/obesity and DM/CVD.Prasenjit and Sushil²¹, in 2015, systematically explained how obesity exacerbates inflammatory responses through oxidative stress, thereby increasing the risk of T2DM and CVD. This deepened the understanding of the molecular mechanisms underlying obesity-related metabolic disorders. As research progressed, Piché et al.²² proposed in 2020 that the phenotypic heterogeneity of obesity has diverse health impacts, with visceral fat accumulation significantly increasing the risk of CVD and DM. Further studies indicated that while overall obesity increases risk, the accumulation of fat in specific regions has a more pronounced effect on metabolic and cardiovascular health²³.In 2021, the AHA issued a statement²⁴ systematically summarizing the relationship between obesity and CVD. It explicitly identified obesity as an independent risk factor for CVD while emphasizing the close relationship between obesity and T2DM. Moreover, the statement highlighted key areas for future research, such as developing upstream interventions

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

for young, severely obese patients for primary prevention and better chronic disease management. For older populations at risk of heart failure, strategies should focus on weight maintenance and improving functional outcomes rather than weight loss alone. Public Health Strategies for Diet and Exercise. In 2010, Micha Renata et al.²⁵ evaluated the differential health impacts of red and processed meat consumption. Their study indicated a significant positive correlation between processed meat intake and the risk of coronary heart disease and DM, while unprocessed red meat showed no such significant association. Subsequent research corroborated these findings, such as a meta-analysis published in BMC Public Health²⁶ in 2019 and a study based on UK Biobank data²⁷ in 2022. This accumulating scientific evidence has begun to influence global public health policies, with the World Health Organization²⁸, the International Agency for Research on Cancer (IARC)²⁹, and the European Society of Cardiology(ESC)³⁰ all emphasizing the importance of reducing processed consumption. Beyond studies on specific foods, broader lifestyle interventions have also made significant progress. In 2015, Pedersen³¹ comprehensively reviewed the evidence for exercise as a treatment modality in 26 chronic diseases, highlighting the substantial effect of regular physical activity combined with dietary interventions in reducing DM and cardiovascular disease (CVD) risk. In 2016, Mozaffarian Dariush³² published a review in Circulation, integrating the latest dietary scientific evidence and emphasizing the importance of specific foods and overall dietary patterns (such as the Mediterranean diet) in preventing and managing chronic diseases. Meanwhile, polyphenol research has provided new perspectives on lifestyle interventions. A 2015 review³³ indicated that antioxidant phytochemicals like polyphenols can effectively scavenge excess oxidants, reducing oxidative stress levels. In 2018, Nour et al.³⁴ further elucidated the

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

immunomodulatory and anti-inflammatory mechanisms of polyphenols, including immune cell regulation, inhibition of pro-inflammatory factors, and inactivation of NF-kB. These mechanisms demonstrate the potential benefits of polyphenols in preventing and managing various chronic diseases, particularly in improving insulin sensitivity and vascular function. In 2020, Mehdi et al.35 conducted an in-depth analysis of the relationship between oxidative stress and various metabolic diseases, proposing lifestyle adjustments (such as increasing antioxidant intake and maintaining regular exercise) to improve oxidative stress status and thereby reduce disease burden. This research further reinforced the importance of antioxidants like polyphenols in chronic disease prevention. However, despite encouraging results from polyphenol research, Hannah et al.'s review³⁶ pointed out that currently only a few specific polyphenol compounds have received official approval for health claims, highlighting the need for enhanced regulation and research in this area. Additionally, the impact of food processing on polyphenol bioavailability requires further investigation to optimize their application in daily diets. Theoretical Advances in the Mechanistic Research of DM+CVD. The pathophysiological mechanism research of DM+CVD involves complex interactions across multiple levels and disciplines. Through systematic analysis of highly cited literature, we have identified three main research directions: (1) Reassessmentof adipose tissue function, (2) In-depth study of cellular signaling pathways, and (3) Regulatory role of miRNAs in disease progressionThese studies reveal the complex pathophysiological processes of the disease from different perspectives, providing important clues for understanding disease mechanisms and developing new therapeutic strategies.

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

The reassessment of adipose tissue function is an important breakthrough in DM+CVD research. In 2008, Hajer et al. published a comprehensive review in the European Heart Journal³⁷, summarizing the significant advances in the scientific community's understanding of adipose tissue function at that time. This review emphasized that adipose tissue is not merely a simple fat storage site, but plays a key role in metabolic regulation and endocrine function. Adipose tissue directly participates in the pathophysiological processes of DM and CVD by secreting various hormones and cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1). These findings provided new perspectives for subsequent research, prompting researchers to reconsider the associations between obesity, DM, and CVD Research on cellular signaling pathways has further deepened our understanding of disease mechanisms. In 2010, Geraldes Pedro and King George L³⁸ reviewed the potential role of protein kinase C (PKC) isoforms in the treatment of DM complications, which garnered widespread attention in the research community³⁹. Although Ruboxistaurin, a PKC-β inhibitor, has shown promise in the treatment of diabetic retinopathy, further studies are needed to confirm its efficacy and safety in cardiovascular protection⁴⁰. Research on microRNAs (miRNAs) has provided new insights into disease mechanisms^{41,42}. In 2012, Creemers Esther E et al. 43 reviewed the progress in circulating miRNAs (miRNAs present in body fluids such as blood) research in CVD, highlighting their potential value as biomarkers. While the potential of circulating miRNAs as biomarkers has gained widespread attention, the fundamental challenges in their clinical application may be more profound. These include large individual variations in circulating miRNA expression⁴⁴ standardization issues in

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

detection methods⁴⁵, consistency in sample collection and processing⁴⁶ and the complexity in interpreting the origins and functions of circulating miRNAs⁴⁷. Currently, these challenges limit the reliability of circulating miRNAs as diagnostic tools. In terms of therapeutic theory research. Recent studies have not only deepened our understanding of existing treatments but also paved the way for personalized and precision medicine.Metformin, a cornerstone in DM treatment, has been a focus of research regarding its mechanism of action and clinical applications. A highly cited paper published in Cell Metabolism in 2014⁴⁸elaborated on its mechanism and potential cardiovascular benefits. Despite metformin's crucial role in DM treatment, its use may increase the risk of lactic acidosis in patients with renal impairment and high-risk cardiovascular conditions⁴⁹, necessitating caution. These challenges, however, present opportunities for precision medicine, enabling more precise and safer individualized treatment strategies through the study of drug characteristics in different populations and clinical contexts. In 2016, Wang et al. 50 comprehensively updated recent research findings in a review article in Circulation. They noted that current treatment strategies primarily focus on glycemic control, overlooking other important mechanisms by which DM exacerbates atherosclerosis and heart failure, such as chronic inflammation and endothelial dysfunction, which may vary in presentation and impact among patients. These findings highlight the necessity of personalized treatment approaches⁵¹.In the same year, Kautzky-Willer et al.⁵² further emphasized the importance of individualized treatment by analyzing the multifaceted impact of gender differences in T2DM. This study provided crucial evidence for developing gender-specific treatment strategies, though more clinical trials are needed to validate their efficacy. Forrester et

al.⁵³, in a 2018 Circulation Research paper, delved into the mechanisms of reactive oxygen

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

species (ROS) in metabolic and inflammatory signaling, discussing potential strategies for treating related diseases by modulating ROS levels and signaling pathways. This study not only deepened the understanding of oxidative stress in DM+CVD but also suggested new approaches for targeting ROS-related pathways. However, translating these basic research findings into clinical applications faces numerous challenges, including precise control of ROS levels, potential dose-dependent side effects, and individual variations in ROS metabolism, all of which require further investigation. These challenges continue to drive the development of precision medicine in the field of DM+CVD. 3.2Article. We analyzed 28 articles from the top 50 highly cited papers. Based on their research topics, we categorized these articles into three main groups: epidemiological studies, clinical research advancements in DM+CVD diagnosis and treatment, and management strategies. In terms of epidemiological research. we conducted a comprehensive analysis of 7 relevant highly cited publications. We integrated the associated data and perspectives, summarizing their content and significant implications for public health. he incidence and prevalence of CVD and DM continue to rise, and despite an overall slowdown in mortality rates, these two diseases remain among the leading causes of death globally^{54,55} The age-standardized prevalence of DM worldwide increased by 90.5% from 1990 to 2021, with the number of patients rising from 108 million in 1980 to approximately 529 million in 2021, of which 96% were T2DM patients⁵⁶. The risk of CVD prevalence increases with age. Data from the NHLBI's Framingham Heart Study (FHS) show⁵⁷ that between 1980 and 2003, the annual incidence of first CVD events rose from 3/1000 in men aged 35-44 to 74/1000 in men aged

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

85-94. The number of CVD cases increased from 271 million in 1990 to 523 million in 2019^{58,59}. Regarding mortality, the age-standardized death rate (per 100,000 population) for DM increased from 18.2 in 1990 to 19.6 in 2021. Although the age-standardized death rate for cardiovascular and circulatory system diseases decreased by 22% between 1990 and 2013⁵⁵, considering global demographic changes, the number of CVD deaths continues to rise. As of 2021, CVD deaths still accounted for one-third of global deaths⁵⁹. There is a strong link between DM and CVD. Studies show⁴⁷ that for every 10-year increase in DM duration, the risk-factor-adjusted CVD risk increases by 1.38-fold, and the mortality risk increases by 1.86-fold. Although the incidence of CVD events among adult DM patients has decreased by 50% since the beginning of the 21st century, the absolute risk of CVD remains twice that of non-DM populations⁵³.DM+CVD imposes a significant disease burden on global public health, with notable regional disparities^{54,55,60} In economically developed countries such as the United States and Western European nations, despite declining mortality rates for DM and CVD, incidence continues to rise, primarily attributed to population aging and increasing obesity rates^{57,61}. In contrast, low- and middle-income countries exhibit high rates of both incidence and mortality for DM and CVD, potentially due to lower education levels and awareness of prevention and control, weaker treatment capabilities, and insufficient healthcare resources^{62–64}. These studies collectively emphasize the persistent nature of DM and CVD as major global health threats. They provide crucial evidence for developing effective public health strategies to address current health challenges, particularly in areas such as resource allocation, implementation of preventive measures, and healthcare system reforms. Future research should further explore prevention and management strategies for these diseases, especially in resource-limited regions.

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

Clinical research advancements in DM+CVD diagnosis and treatment. Among the highly cited publications, 11 articles are related to this topic, covering biomarker studies, inflammation, and pharmaceutical research. Biomarker researchplays a crucial role in the diagnosis and management of DM and CVD⁶⁵, deepening our understanding of disease mechanisms and providing new directions for diagnostic, preventive, and therapeutic strategies. In 2007, Goralski et al.66 identified Chemerin as a novel adipokine that promotes insulin resistance by influencing insulin signaling and glucose metabolism, emerging as a new biomarker for DM⁶⁷. Moreover, Chemerin increases CVD risk by promoting vascular inflammation and endothelial dysfunction, making it significant in cardiovascular risk assessment⁶⁸. In 2017, Ellulu et al. provided a multidimensional perspective on DM+CVD biomarker research69, revealing the complex interactions between obesity, chronic inflammation, and oxidative stress in DM+CVD pathogenesis. They found a negative correlation between pro-inflammatory factors (TNF-α, IL-6) and adiponectin levels, while CRP levels strongly correlated with CVD risk. This finding not only linked metabolic disorders with vascular pathology but also provided a theoretical basis for multi-target therapeutic strategies. However, these highly cited studies also reveal several challenges in biomarker application. Firstly, single biomarkers often fail to fully reflect the complex pathophysiological characteristics of DM and CVD⁶⁹ suggesting that future research may need to develop multi-marker combination models. Secondly, these studies emphasize the importance of individual differences, as factors such as race, age, and gender may influence biomarker expression and significance⁷⁰. Overall, the rapid advancement in biomarker research has opened new opportunities for elucidating

mechanisms, diagnosis, and treatment of DM+CVD. Nevertheless, to translate these research

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

findings into clinical practice, more large-scale, multicenter prospective studies are needed to validate their clinical application value. Inflammation plays a crucial role in understanding the pathophysiological mechanisms of diseases. In 2018, Ferrucci and Fabbri⁷¹ scientifically elucidated the roles of monocytes, macrophages, T cells, B cells, cellular senescence, and senescence-associated secretory phenotype (SASP) in CVD pathogenesis. These factors contribute to CVD risk by promoting the release of inflammatory mediators and exacerbating inflammatory responses. Numerous studies have corroborated this perspective^{71–74}. Regulating endothelial nitric oxide synthase (eNOS) activity and function is an effective approach to mitigate inflammatory responses. However, eNOS "uncoupling" can transform it into a superoxide (O₂-) generating enzyme, thereby aggravating inflammation and CVD progression. Förstermann⁷⁵ noted that increasing tetrahydrobiopterin (BH4) levels or inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity could correct eNOS dysfunction, thus restoring its protective effects. In the complex pathological network of DM+CVD, inflammatory response serves as a critical link, with implications far beyond mere cytokine release. DM patients, chronically exposed to hyperglycemia, not only experience low-grade inflammation but also undergo fundamental alterations in immune balance and metabolic regulation ⁷⁶. This systemic dysregulation accelerates atherosclerosis progression through multidimensional, multilayered mechanisms, creating a self-perpetuating cycle^{77,78}. Furthermore, we need to reconsider the dual role of inflammation in DM+CVD. While excessive inflammation is undoubtedly harmful, moderate inflammatory responses are necessary for tissue repair and metabolic homeostasis⁷⁹. Therefore, future therapeutic strategies should aim

not to completely eliminate inflammation, but rather to reestablish a healthy inflammatory balance, necessitating more refined regulatory approaches and long-term intervention strategies.

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

Pharmaceutical research. In recent years, DM and CVD-related drug research has shown trends towards diversification and precision. Analysis of highly cited literature reveals that hot topics in drug research focus on sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), statins, antiplatelet drugs, renin-angiotensin-aldosterone system (RAAS) inhibitors, and β-blockers^{80–82}. These drugs not only target glycemic control but also reflect multi-target intervention strategies for cardiovascular protection. The emergence of SGLT2i and GLP-1 RA, in particular, has provided new treatment options for DM+CVD patients, potentially altering clinical practice patterns. However, despite GLP-1 RA showing significant effects in DM treatment⁸³, its role in preventing cardiovascular events remains controversial. A large-scale randomized controlled trial (RCT) by Pfeffer et al.80 demonstrated that lixisenatide was non-inferior to placebo in terms of major cardiovascular endpoint incidence in T2DM patients with acute coronary syndrome, but failed to prove its superiority. This finding challenges our traditional understanding of incremental drug efficacy while highlighting the difficulty of evaluating single intervention effects in complex disease networks.

Another important point is the role of antiplatelet therapy in primary prevention of DM+CVD warrants further attention. Research by De Berardis et al.⁸⁴revealed gender differences in the effects of low-dose aspirin and its potential bleeding risks. This finding not only emphasizes the importance of individualized treatment but also reflects the need for a more comprehensive consideration of the balance between risks and benefits when evaluating preventive interventions.

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

Ten articles are related to this topic. The Comprehensive management strategies. combined management of DM and CVD is a complex process aimed at comprehensively reducing cardiovascular risk and improving patients' long-term prognosis and quality of life86. This requires consideration of multiple factors, including glycemic control, blood pressure management, lipid regulation (such as lowering LDL-C levels), weight management, and control of other cardiovascular risk factors. Achieving these goals necessitates addressing three core aspects: patient self-education and self-management, lifestyle interventions, and risk assessment. Patient self-management and self-education have undergone significant evolution over the past two decades, progressing from basic disease awareness education to comprehensive multifactorial interventions, and now to technology-driven precision management. In 2007, the AHA and American Diabetes Association (ADA)85, along with the ESC and European Association for the Study of Diabetes (EASD)86, proposed fundamental frameworks for patient self-management in their respective joint guidelines, emphasizing disease awareness, lifestyle interventions, and medication adherence education. This phase focused on enhancing patients' basic understanding of their conditions and encouraging proactive lifestyle changes. As medical knowledge deepened, the 2013 guidelines introduced a more comprehensive management concept⁸⁷. This update expanded beyond singular glycemic control to integrate blood pressure and lipid management, while also incorporating psychological health into the overall management strategy. From 2019 onwards^{88–90} guideline updates reflect characteristics of the digital age, ushering patient self-management into a new era. The introduction of smart devices and telemedicine has created unprecedented possibilities for real-time monitoring and precision management. For

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

instance, the use of continuous glucose monitoring systems (CGM) and smart blood pressure monitors allows patients and healthcare teams to track key indicators more accurately. These technologies not only improve the precision and timeliness of data collection but also enable healthcare teams to respond more rapidly to patient needs, facilitating multidisciplinary collaboration and ongoing support. Lifestyle interventions are an indispensable component in the comprehensive management of DM+CVD. Research by Danaei et al.⁹¹ corroborates the stance of major European and American guidelines, affirming that scientific lifestyle interventions, including dietary control, increased physical activity, and smoking cessation, not only help reduce CVD risk but also improve DM management outcomes. Weight management, as an integrated result of these interventions, emerges as a core objective in preventing and controlling both diseases. Mora et al. 92 further elucidated the importance of appropriate weight management, demonstrating that higher levels of physical activity can significantly reduce cardiovascular event risk through mechanisms affecting blood pressure and inflammation, among others. Concurrently, diet plays a crucial role in management strategies. Healthy dietary habits, particularly those rich in plant polyphenols⁹³, offer cardiovascular protection by improving vascular function, lowering blood pressure, and reducing LDL oxidation. While these studies provide evidence for the efficacy of lifestyle interventions, translating them into clinical practice remains challenging. Factors such as socioeconomic status, healthcare accessibility, and patient adherence often influence intervention outcomes⁹⁴. Therefore, future efforts should focus on tailoring scientific interventions to patients' social resources, sustainability, and individual characteristics. Additionally, exploring methods to enhance long-term adherence

through digital health technologies warrants active investigation.

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

Risk assessment plays a crucial role in early disease prevention and individualized management. The Framingham Heart Study⁹⁵ provided a multifactorial risk assessment model for evaluating overall and specific CVD risks in primary care. This multivariate risk assessment approach advanced cardiovascular disease prevention strategies and laid the foundation for subsequent risk assessment tool development. In recent years, risk assessment tools in the DM+CVD field have continually evolved, transitioning from traditional static models to more dynamic, personalized approaches. Updates to tools such as the QRISK3 cardiovascular risk assessment⁹⁶, Finnish Diabetes Risk Score⁹⁷, and dynamic heart failure risk prediction models⁹⁸ showcase advantages in integrating more dynamic data sources, considering a broader range of risk factors, and utilizing advanced statistical and machine learning methods. These advancements enable clinicians to formulate more targeted prevention and treatment strategies. Regarding blood glucose and blood pressure monitoring, CGM and home blood pressure monitoring (HBPM) have become increasingly recommended methods. CGM technology provides real-time, continuous monitoring of blood glucose levels, offering DM patients valuable insights into glucose fluctuations⁹⁹. HBPM supplies authentic blood pressure data from patients' daily lives, avoiding interference from "white coat effect" and "masked hypertension". HBPM data contributes to more accurate assessment of antihypertensive treatment efficacy, facilitating timely medication adjustments. Long-term HBPM data can also reveal circadian blood pressure rhythm changes, providing clues for identifying abnormal blood pressure patterns. In conclusion, these studies indicate that management strategies for DM+CVD are evolving towards more integrated, precise, and personalized approaches. The development of

technology-driven precision management models, individualized lifestyle intervention programs, and dynamic risk assessment tools presents increased possibilities for improving the efficacy of DM+CVD combined management. However, it is important to acknowledge that implementing these comprehensive management strategies still faces challenges in translating theory into practice, particularly when considering individual patient differences and socioeconomic factors. Future research should focus on enhancing the translational impact of new technologies, improving patient adherence, and developing more individualized and dynamic risk assessment models to achieve precision management of DM and CVD.

4.Research Hotspots and Development Trends

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

We attempted to discuss the research hotspots and trends in the field of DM+CVD by analyzing highly co-cited literature and their keywords from the past three years (2021-2023). The Citespace keyword analysis and its Spotlight function results are shown in Figure 8A. The Spotlight function of Citespace helps researchers quickly identify keywords that are widely cited and have significant impact on the current research field17. The results indicate that the main keywords are Cardiovascular disease, Risk, Oxidative stress, Inflammation, Obesity, Heart failure, Body mass index, Adipose tissue, Mortality, and Insulin resistance. This suggests that current research trends continue to revolve around these important and persistent hot topics. FIG 8. Visualization of Highly Cited Literature Keywords and Time line in DM+CVD (2021-2024)(A) Keyword co-occurrence network generated by CiteSpace. Node and font size represent the intensity and frequency of keyword occurrence. Node color indicates different time periods, with darker colors representing more recent times. Links between nodes, determined by the Spotlight

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

algorithm, indicate high correlation between keywords. (B) Timeline view of major research topics. Each colored line represents a distinct research theme, with nodes on the lines indicating specific topics. The curvature and span of each line demonstrate the emergence and fading of different research themes over time. Among the keywords, those in smaller fonts reflect emerging research directions gaining gradual attention, such as metabolic flexibility¹⁰⁰, development of mitochondria-targeted therapeutic strategies¹⁰¹, and the role of epigenetics in cardiovascular diseases¹⁰². This indicates that researchers have been exploring more refined and individualized disease mechanisms and treatment approaches in recent years. Through the Spotlight algorithm, we observed significant associations between several groups of keywords, such as obesity and adipose tissue, cardiovascular disease and heart failure, and oxidative stress and inflammation. These close associations reflect the evolution and deepening of research focus over the past three years, while also revealing researchers' in-depth exploration of internal connections within specific topics. Specifically, the link between obesity and adipose tissue indicates that research is delving into the complex relationship between obesity and adipose tissue function, particularly in terms of metabolic disorders and cardiovascular risk103. The association between cardiovascular disease and heart failure suggests the increasing importance of heart failure in DM+CVD research¹⁰⁴, possibly related to population aging and improvements in chronic disease management. The close connection between oxidative stress and inflammation demonstrates researchers' growing recognition of the interplay between these two processes in various pathological states¹⁰⁵. Clustering of keywords yielded six categories, as shown in Figure 8B: #0 Inflammation, #1 Diabetic cardiomyopathy, #2 Risk factors, #3 Coronary artery disease, #4 Type 2 diabetes, and #5

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

Cell. The Inflammation cluster emphasizes the central role of inflammation in DM+CVD pathology, possibly involving the development of novel anti-inflammatory therapeutic strategies. The Diabetic cardiomyopathy cluster suggests that researchers may be delving into the specific effects of DM on the myocardium. The Risk factors cluster reflects ongoing attention to DM+CVD risk prediction and prevention. The Coronary artery disease cluster underscores the pivotal position of coronary artery disease in DM+CVD. The Type 2 diabetes cluster emphasizes the close link between T2DM and CVD. The Cell cluster likely involves cellular-level mechanism studies, such as endothelial dysfunction or myocardial cell metabolic abnormalities. Overall, these clusters span multiple levels from basic research to clinical applications, reflecting the complexity and multidisciplinary nature of DM+CVD research. They also hint at potential breakthroughs in future research. Future studies may focus more on the connections between these different themes to gain a more comprehensive understanding of DM+CVD. In the previously mentioned trends in DM+CVD pharmacological research, SGLT2 inhibitors and GLP-1 receptor agonists have become the focus of recent studies due to their multiple clinical benefits. The proportion of highly cited literature in the past three years further confirms the importance of these drugs. Among the 10 articles, 4 involve SGLT2 inhibitors and GLP-1 receptor agonists.In 2016, Zinman et al¹⁰⁶ published a study in NEW ENGL J MED with a median observation time of 3.1 years, concluding that for individuals with T2DM and high CVD risk, using SGLT2 inhibitors as adjunctive therapy reduced the rates of major cardiovascular events and all-cause mortality. In the same year, Marso et al¹⁰⁷conducted a study with a median follow-up of 3.8 years, finding that liraglutide (a GLP-1 receptor agonist) significantly reduced cardiovascular event risk in T2DM, particularly cardiovascular death risk. This finding supports

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

the inclusion of liraglutide in treatment regimens for type 2 diabetes patients with high cardiovascular risk. Also in 2016, Heerspink et al⁸¹ retrospectively examined the significant cardiovascular and renal protective effects of SGLT2 inhibitors in treating DM and discussed their clinical applications, suggesting that SGLT2 inhibitors should be prioritized when treating diabetic patients with high cardiovascular disease risk. In 2022, Solomon et al¹⁰⁸conducted a randomized, double-blind, placebo-controlled trial, concluding that SGLT2 inhibitors significantly reduced the risk of worsening heart failure and cardiovascular death in patients with mildly reduced or preserved ejection fraction heart failure, while improving patient symptoms. The results of this study have significantly impacted clinical practice in using the SGLT2 inhibitor dapagliflozin to treat this type of heart failure patient. Traditional T2DM management primarily focused on glycemic control, often utilizing insulin and sulfonylureas¹⁰⁹. Cardiovascular disease prevention and treatment relied on statins, antihypertensives, and antiplatelet agents¹¹⁰. This segregated approach potentially led to several issues: dispersed treatment goals, increased risk of drug interactions, high medication burden for patients, potential side effects such as hypoglycemia and weight gain, lack of synergistic effects, and difficulties in achieving personalized precision treatment^{109,111}. In contrast, SGLT2 inhibitors and GLP-1 receptor agonists offer multifaceted clinical benefits in T2DM treatment. Moreover, these agents simultaneously improve glycemic control and cardiovascular health, thereby enhancing overall treatment efficacy and long-term prognosis^{106–108}. Based on their comprehensive therapeutic effects and favorable safety profiles, authoritative bodies such as the ADA and EASD have prioritized SGLT2 inhibitors and GLP-1 receptor agonists in their clinical guidelines specific high-risk diabetic for

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

patients^{89,112}. Consequently, the mechanisms of action of SGLT2 inhibitors and GLP-1 receptor agonists remain a key focus of current and future research, particularly their physiological effects related to sodium metabolism. This ongoing investigation aims to better understand and apply these agents in the integrated management of DM and CVD. Among the 10 articles, 2 discuss the association between lipids, obesity, and DM+CVD. The 2019 ESC/EAS⁸⁹ guidelines on dyslipidemia management detail how to reduce CVD risk through lipid modulation. The guidelines emphasize early lipid risk intervention and lifestyle changes to effectively lower cardiovascular risk. For obese and DM patients, they particularly stress comprehensive management strategies to improve metabolic status and cardiovascular health. In 2021, the AHA released a scientific statement²⁴ on obesity and cardiovascular disease, identifying obesity as a major risk factor for various cardiovascular diseases. It directly increases cardiovascular disease incidence by inducing metabolic abnormalities such as dyslipidemia, hypertension, and T2DM. The AHA emphasizes the importance of lifestyle interventions and weight loss for obesity prevention and treatment. These two authoritative statements have profoundly influenced academia, clinical practice, public health policy, and public health education, advancing the comprehensive management and prevention of obesity and DM+CVD. Although the relationships between obesity, DM, and CVD have been extensively studied, we believe current and future research trends will continue to focus on these areas. This ongoing focus is driven by several factors: the rising global prevalence of obesity¹¹³, DM, and CVD^{59,64}; the crucial role of lipid metabolism abnormalities in these diseases⁹⁰; the incompletely elucidated complex pathophysiological mechanisms; increasing demands for personalized medicine^{114,115}; the

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

emergence of novel therapeutic approaches; and the necessity for multidisciplinary comprehensive management¹¹⁶. Through multidisciplinary collaboration and personalized strategies, the aim is to comprehensively enhance the prevention and management of obesity, DM, lipid metabolism disorders, and CVD. In the highly cited literature, three articles focus on the management of heart failure and cardiomyopathy. The 2016 ESC guidelines for heart failure treatment emphasized the importance of cardiac rehabilitation and self-management education, establishing the foundation for recent heart failure management¹¹⁷ These guidelines established ACE inhibitors, β-blockers, and MRAs as standard treatment regimens, detailed the diagnostic steps for heart failure, including clinical assessment, imaging, and laboratory tests, and introduced BNP and NT-proBNP as diagnostic tools. Additionally, they described acute heart failure management strategies in detail. Building on the 2016 guidelines, the 2021 ESC guidelines¹¹⁸ incorporated new drugs such as SGLT2 inhibitors and ARNIs, refined ejection fraction classification, strengthened the use of BNP and NT-proBNP, and further emphasized personalized treatment based on patient-specific factors, including age and comorbidities. In 2019, Murtaza et al. systematically reviewed the research progress on diabetic cardiomyopathy (DCM)¹¹⁹ exploring the roles of metabolic abnormalities, oxidative stress, and inflammatory responses in DCM pathogenesis. They highlighted the potential of novel drugs, gene therapy, stem cell therapy, and lifestyle interventions in future treatments. This comprehensive review significantly impacted the advancement of early diagnosis and effective treatment of DCM. Although coronary heart disease remains a primary research focus, its study is relatively mature, with declining incidence and mortality rates in many countries and regions globally⁵⁹.

However, heart failure's poor end-stage outcomes¹²⁰ new opportunities for drug development¹²¹

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

123, prospects in regenerative medicine 124 and the multiple complications and substantial medical burden of heart failure patients^{125,126} further underscore the importance and urgency of in-depth research into this disease. Moreover, the complex relationship between cardiomyopathy and diabetes, with their comorbidity and specific mechanisms not fully elucidated, adds another layer of complexity. The emergence of COVID-19 as a new etiological factor and the impact of long COVID have further complicated cardiomyopathy and increased its prevalence. Tegan et al.'s study¹²⁷ found that COVID-19 patients have a 15.7-fold higher risk of myocarditis compared to non-infected individuals. Considering these analyses, we believe that heart failure and cardiomyopathy will gradually become focal points of research in the DM+CVD field in the future. Among the highly cited literature, one article focuses on epidemiological research. The International Diabetes Federation's 2021 Diabetes Atlas (102nd edition)¹²⁸ provides the latest data and projections on the global epidemiology of DM. This report reveals a significant growth trend in DM prevalence in developing countries and emphasizes the potential value of novel drugs such as SGLT2 inhibitors and GLP-1 receptor agonists in disease management. It also stresses the importance of early diagnosis and personalized treatment. Furthermore, the report proposes multifaceted intervention strategies, including strengthening public health education, promoting healthy lifestyles, and improving access to medical services and medications. This comprehensive and systematic report provides valuable reference for formulating DM prevention and control policies, holding significant implications for improving global DM prevention, treatment, and management.

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

Epidemiological research has consistently played a crucial role in DM+CVD prevention and control, and we believe it will remain a key research direction in the future¹²⁹. Epidemiological studies not only help us understand disease distribution, development trends, and influencing factors but also provide scientific evidence for effective public health policy formulation¹³⁰. Ongoing epidemiological surveillance and research are essential for evaluating the effectiveness of interventions, predicting disease burden, optimizing resource allocation, and developing long-term prevention and control strategies. Considering that DM patients often face a higher risk of CVD, epidemiological research has unique advantages in revealing the association between these two types of diseases, exploring common risk factors, and assessing the effectiveness of comprehensive prevention and control strategies¹³¹. In the future, with the development of big data and artificial intelligence technologies, epidemiological research is expected to play a greater role in disease warning, precision prevention, and personalized management, making more contributions to global DM and CVD prevention and control efforts. In summary, we find that the current and future development directions in DM+CVD are not about replacing traditional pathways, but rather about posing new challenges and updates to existing treatment and research methods. Traditional sulfonylureas and statins have shown some efficacy in treating DM or CVD individually, but face challenges when addressing DM combined with CVD or more complex situations. The impact of obesity and abnormal lipid metabolism in DM+CVD patients cannot be overlooked; while weight reduction and lipid metabolism regulation have demonstrated significant clinical benefits in improving prognosis for these patients, their mechanisms of action and optimal intervention strategies are not yet fully elucidated. Although coronary heart disease still dominates DM+CVD research, heart failure and cardiomyopathy are

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

gradually becoming focal points in this field, considering the various clinical scenarios in reality and the complexities associated with their poor end-stage manifestations. Epidemiological research is crucial for understanding the complex relationship between DM and CVD. As global population structure, socioeconomic environments, and risk factors change, such research helps identify and quantify risk factors, providing a scientific basis for developing prevention and management strategies. Therefore, we summarize the current and future development directions as: (1) Intensifying research on novel drugs such as SGLT2 inhibitors and GLP-1 receptor agonists; (2) Updating our understanding of the key roles of obesity and lipid metabolism in disease progression; (3) Focusing on heart failure and cardiomyopathy as the main diseases of study in this field; (4) Strengthening epidemiological research on DM+CVD. **5.**Conclusion and Future Perspectives This study employs bibliometric methods, utilizing CiteSpace and VOSviewer analytical tools, to conduct a systematic analysis of 5,505 relevant publications from 2005 to 2024, aiming to elucidate research dynamics and future trends in the field. Initially, we examined and analyzed publication distribution, countries/regions, institutions, and author productivity and collaborations. We observed a significant growth trend in DM+CVD research, reflecting both sustained academic interest in the field and the increasing recognition of DM+CVD as a complex disease combination. Regarding research collaboration networks, we noted an interesting geographical distribution pattern. While the United States and China dominate in publication volume, European countries, particularly Sweden, stand out in rankings of highly productive authors and institutions.

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

This distribution reflects the global nature of DM+CVD research while potentially indicating regional differences in research priorities. Subsequently, we focused on keywords and highly cited literature. After a comprehensive evaluation of the 5,505 publications from 2005-2024, we analyzed 50 highly cited papers in depth, including 22 reviews and 28 original research articles. Special attention was given to research developments in the past three years (2021-2023) to better understand future trends in the field. The review analysis reveals the evolution of the theoretical framework in DM+CVD research. Specifically, in studying obesity and disease relationships, the perspective has shifted from viewing obesity as a simple disease risk factor to recognizing its phenotypic heterogeneity and differential impact on DM and CVD, ultimately emphasizing multi-level prevention and intervention strategies across the life course. In lifestyle intervention and public health research, the focus has progressed from examining the health effects of single food components to studying the combined role of overall dietary patterns and regular exercise, and finally to integrating dietary interventions into broader public health policy frameworks. Mechanistic studies have demonstrated in-depth exploration at multiple biological levels, including reassessment of tissue function, deeper investigation of cellular signaling pathways, and new discoveries in molecular regulatory mechanisms. Treatment strategies have advanced from single-disease management models to comprehensive risk control and individualized precision therapy. Analysis of original research illustrates the development from theory to clinical practice. Epidemiological studies have quantified the global disease burden of DM+CVD, providing empirical evidence for evidence-based public health strategies. Clinical diagnosis and treatment research encompasses the identification of novel biomarkers, elucidation of inflammation's central

role in disease pathophysiology, and efficacy validation of new drugs. Management strategy research reflects a transition from basic awareness education to technology-driven, multi-factorial, and multi-disease comprehensive risk control. Finally, through analysis of highly cited literature from the past three years, we identified or predicted future research priorities in the field, including: novel drug intervention strategies, pathophysiological associations between metabolic abnormalities and DM+CVD, precision management of cardiovascular complications, and more extensive epidemiological research. In nearly two decades, despite significant advancements in this field, we have identified several persistent challenges. The long-term effects and precise mechanisms of novel drugs require further investigation. Clinical application of biomarkers faces issues of standardization and individualization. Achieving a precise balance in inflammation regulation remains a complex problem. Notably, effectively preventing and managing obesity at the population level to reduce DM+CVD incidence continues to be a major challenge. In general, DM+CVD research is evolving from descriptive and observational studies towards mechanism-oriented and personalized approaches, with obesity consistently emerging as a key factor. Looking ahead, interdisciplinary collaboration and translational medical research will play crucial roles in driving breakthrough progress in the DM+CVD field, particularly in deciphering the complex relationships between obesity and DM+CVD. This not only holds promise for improving patient outcomes but may also provide insights for managing other obesity-related complex chronic diseases.

Acknowledgments

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

We thank the Science and Technology Department of Xinjiang Uygur Autonomous Region and

perpetuity.

It is made available under a CC-BY 4.0 International license.

893 the Science and Technology Bureau of Hetian Prefecture for supporting this research. 894 REFERENCES 895 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes 896 1. Care. 2014;37 Suppl 1:S81-90. doi:10.2337/dc14-S081 897 American Diabetes Association Professional Practice Committee. 2. Classification and 898 2. Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022[J/OL]. Diabetes Care, 899 900 2022, 45(Suppl 1): S17-S38 901 3. Javeed N, Matveyenko AV. Circadian Etiology of Type 2 Diabetes Mellitus. Physiology 902 (Bethesda). 2018;33(2):138-150. doi:10.1152/physiol.00003.2018 903 4. Szmuilowicz ED, Josefson JL, Metzger BE. Gestational Diabetes Mellitus. Endocrinol Metab 904 Clin North Am. 2019;48(3):479-493. doi:10.1016/j.ecl.2019.05.001 905 Home, Resources, Living with diabetes, et al. IDF Diabetes Atlas 2021 | IDF Diabetes Atlas. 5. 906 Accessed March 4, 2024. https://diabetesatlas.org/atlas/tenth-edition/ 907 Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes 6. 908 Care. 2023;47(1):26-43. doi:10.2337/dci23-0085 909 7. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes. 2008;26(2):77-82. doi:10.2337/diaclin.26.2.77 910 911 8. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 insulin-treated diabetes. Diabetologia. 2003;46(6):760-765. 912 patients with 913 doi:10.1007/s00125-003-1116-6 914 9. Thomas A. Zelniker, Eugene Braunwald. Mechanisms of Cardiorenal Effects of 915 Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll 916 Cardiol. 2020;75(4):422-434. doi:10.1016/j.jacc.2019.11.031 917 Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. Heart Views. 918 2017;18(3):109-114. doi:10.4103/HEARTVIEWS.HEARTVIEWS_106_17 919 Chu X, Feng B, Ge J, et al. Chinese expert consensus on the risk assessment and 920 management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition). Cardiology Plus. 2022;7(4):162-177. doi:10.1097/CP9.0000000000000029 921 922 Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS, Diabetes Control and 923 Complications Trial/Epidemiology of Diabetes Interventions and Complications Research 924 Group. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: 925 the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and

- 926 Complications study. Diabetes Care. 2007;30(8):2107-2112. doi:10.2337/dc06-1441
- 927 Thomas R. Einarson, Annabel Acs, Craig Ludwig, Ulrik H. Panton. Prevalence of
- 928 cardiovascular disease in type 2 diabetes: a systematic literature review of scientific
- 929 evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
- 930 doi:10.1186/s12933-018-0728-6
- 931 Hou Q, Li Y, Li S, Tian H. The global burden of diabetes mellitus. Chinese Journal of
- 932 Diabetes. 2016;24(1):92-96. doi:10.3969/j.issn.1006-6187.2016.01.023.
- 933 Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping Knowledge Landscapes and
- 934 Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A
- 935 2000 2021. Bibliometric Analysis From to Front Public Health. 2022;10.
- 936 doi:10.3389/fpubh.2022.918483
- 937 Lv J, Li Y, Shi S, et al. Frontier and Hotspot Evolution in Cardiorenal Syndrome: A
- 938 Bibliometric Analysis From 2003 to 2022. Current Problems in Cardiology.
- 939 2023;48(8):101238. doi:10.1016/j.cpcardiol.2022.101238
- 940 Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric
- 941 analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593-608.
- 942 doi:10.1517/14712598.2012.674507
- 943 van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric 18.
- 944 mapping. Scientometrics. 2010;84(2):523-538. doi:10.1007/s11192-009-0146-3
- 945 S. R. Daniels, D. K. Arnett, R. H. Eckel, et al. Overweight in children and adolescents -
- 946 Pathophysiology, consequences, treatment. Circulation. prevention, and
- 947 2005;111(15):1999-2012. doi:10.1161/01.CIR.0000161369.71722.10
- 948 Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
- 949 co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
- 950 BMC Public Health. 2009;9:88. doi:10.1186/1471-2458-9-88
- 951 Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated
- 952 Health Risks: Causes and Therapeutic Strategies. Metab Syndr Relat Disord.
- 953 2015;13(10):423-444. doi:10.1089/met.2015.0095
- 954 Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular
- 955 Diseases. Circ Res. 2020;126(11):1477-1500. doi:10.1161/CIRCRESAHA.120.316101
- 956 Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 23.
- 2012;126(10):1301-1313. doi:10.1161/CIRCULATIONAHA.111.067264 957
- 958 Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific
- 959 Statement From the American Heart Association. Circulation. 2021;143(21):E984-E1010.
- doi:10.1161/CIR.00000000000000973 960

961 Micha R, Wallace SK, Mozaffarian D. Red and Processed Meat Consumption and Risk of 25. 962 Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus A Systematic Review and 963 Meta-Analysis. Circulation. 2010;121(21):2271-U52. doi:10.1161/CIRCULATIONAHA.109.924977 964 965 Wang M, Ma H, Song Q, et al. Red meat consumption and all-cause and cardiovascular mortality: results from the UK Biobank study. Eur J Nutr. 2022;61(5):2543-2553. 966 doi:10.1007/s00394-022-02807-0 967 968 Cui K, Liu Y, Zhu L, Mei X, Jin P, Luo Y. Association between intake of red and processed 969 meat and the risk of heart failure: a meta-analysis. BMC Public Health. 2019;19(1):354. 970 doi:10.1186/s12889-019-6653-0 971 World Health Organization. Global Action Plan for the Prevention and Control of 972 Noncommunicable Diseases 2013-2020. Geneva, Switzerland: World Health Organization; 973 2013 974 Wild CP, Weiderpass E, Stewart BW, eds. World Cancer Report: Cancer Research for Cancer 975 Prevention. Lyon, France: International Agency for Research on Cancer; 2020 976 30. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease 977 prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. 978 doi:10.1093/eurheartj/ehw106 979 Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 980 26 different chronic diseases. Scand J Med Sci Sports. 2015;25 Suppl 3:1-72. doi:10.1111/sms.12581 981 982 32. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Comprehensive Circulation. 2016;133(2):187-225. 983 Review. 984 doi:10.1161/CIRCULATIONAHA.115.018585 985 Zhang YJ, Gan RY, Li S, et al. Antioxidant Phytochemicals for the Prevention and Treatment 986 of Chronic Molecules. 2015;20(12):21138-21156. Diseases. 987 doi:10.3390/molecules201219753 988 Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. Nutrients. 2018;10(11):1618. doi:10.3390/nu10111618 989 990 35. Sharifi-Rad M, Anil Kumar NV, Zucca P, et al. Lifestyle, Oxidative Stress, and Antioxidants: 991 Back and Forth in the Pathophysiology of Chronic Diseases. Front Physiol. 2020;11:694. 992 doi:10.3389/fphys.2020.00694

- Cory H, Passarelli S, Szeto J, Tamez M, Mattei J. The Role of Polyphenols in Human Health 993 994 and Food Systems: A Mini-Review. Front Nutr. 2018;5:87. doi:10.3389/fnut.2018.00087
- 995 Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes,

996 and vascular diseases. Eur Heart J. 2008;29(24):2959-2971. doi:10.1093/eurheartj/ehn387 997 38. Geraldes P, King GL. Activation of Protein Kinase C Isoforms and Its Impact on Diabetic 998 Complications. CircRes. 2010;106(8):1319-1331. doi:10.1161/CIRCRESAHA.110.217117 999 Bence Hegyi, Johanna M. Borst, Logan R. J. Bailey, et al. Hyperglycemia regulates cardiac K+ channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways. Basic Res Cardiol. 1000 2020;115(6):71. doi:10.1007/s00395-020-00834-8 1001 1002 He Z, King GL. Can Protein Kinase C β-Selective Inhibitor, Ruboxistaurin, Stop Vascular 1003 Complications in Diabetic Patients? Diabetes Care. 2005;28(11):2803-2805. 1004 doi:10.2337/diacare.28.11.2803 Mardis ER. DNA sequencing technologies: 2006-2016. Nat Protoc. 2017;12(2):213-218. 1005 1006 doi:10.1038/nprot.2016.182 1007 Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26(10):1135-1145. 1008 doi:10.1038/nbt1486 Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs Novel Biomarkers and 1009 43. 1010 Extracellular Communicators in Cardiovascular Disease? CircRes. 2012;110(3):483-495. 1011 doi:10.1161/CIRCRESAHA.111.247452 1012 Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating 1013 miRNAs cancer biomarkers. **Biomed** Res Int. 2015;2015:731479. as 1014 doi:10.1155/2015/731479 1015 Felekkis K, Papaneophytou C. Challenges in Using Circulating Micro-RNAs as Biomarkers for 45. Cardiovascular Diseases. Int J Mol Sci. 2020;21(2):561. doi:10.3390/ijms21020561 1016 1017 Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012;303(9):H1085-1095. 1018 1019 doi:10.1152/ajpheart.00191.2012 1020 47. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from 1021 single biomarkers to re-wired networks. Cardiovascular Research. 2012;93(4):555-562. 1022 doi:10.1093/cvr/cvr266 1023 48. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action to Therapies. Cell Metab. 2014;20(6):953-966. doi:10.1016/j.cmet.2014.09.018 1024 1025 Kwon S, Kim YC, Park JY, et al. The Long-term Effects of Metformin on Patients With Type 2 1026 Diabetic Kidney Disease. Diabetes Care. 2020;43(5):948-955. doi:10.2337/dc19-0936 1027 Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in 50. 1028 Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 1029 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation.

1030 2016;133(24):2459-2502. doi:10.1161/CIRCULATIONAHA.116.022194 1031 Ashley EA. The Precision Medicine Initiative A New National Effort. JAMA-J Am Med Assoc. 1032 2015;313(21):2119-2120. doi:10.1001/jama.2015.3595 1033 52. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology 1034 and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137 1035 1036 Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in 1037 Metabolic and Inflammatory Signaling. CircRes. 2018;122(6):877-+. 1038 doi:10.1161/CIRCRESAHA.117.311401 Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-1039 1040 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-1210. doi:10.1016/S0140-6736(17)32152-9 1041 1042 Global, regional, and national incidence, prevalence, and years lived with disability for 301 55. 1043 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. 1044 1045 doi:10.1016/S0140-6736(15)60692-4 1046 GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1047 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden 1048 of Disease Study 2021. Lancet. 2023;402(10397):203-234. 1049 doi:10.1016/S0140-6736(23)01301-6 1050 Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a 1051 report from the American Heart Association. Circulation. 2013;127(1):e6-e245. 1052 doi:10.1161/CIR.0b013e31828124ad 1053 GBD 2021 CoD infographic 6G 2024.04.03 ZH.pdf. 58. Accessed May 30. 2024. 1054 https://www.healthdata.org/sites/default/files/2024-04/GBD 2021 CoD infographic 6G 1055 2024.04.03 ZH.pdf 1056 Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk 59. 1057 Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010 1058 1059 GBD 2013 DALYs and HALE Collaborators, Murray CJL, Barber RM, et al. Global, regional, 1060 and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological 1061 1062 transition. Lancet. 2015;386(10009):2145-2191. doi:10.1016/S0140-6736(15)61340-X 1063 Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: 1064 A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.

doi:10.1161/CIR.0000000000000659

- 1066 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a
- 1067 pooled analysis of 751 population-based studies with 4.4 million participants. Lancet.
- 2016;387(10027):1513-1530. doi:10.1016/S0140-6736(16)00618-8 1068
- 1069 Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of
- 1070 hypertension in rural and urban communities in high-, middle-, and low-income countries.
- 1071 JAMA. 2013;310(9):959-968. doi:10.1001/jama.2013.184182
- 1072 Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for
- 2019 and projections for 2030 and 2045: Results from the International Diabetes 1073
- 1074 Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
- 1075 doi:10.1016/j.diabres.2019.107843
- 1076 Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in
- 1077 cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.
- 1078 doi:10.1186/s12933-022-01511-x
- 1079 Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates
- 1080 adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282(38):28175-28188.
- 1081 doi:10.1074/jbc.M700793200
- 1082 Zhao L, Zhou J, Abbasi F, et al. Chemerin in Participants with or without Insulin Resistance
- 1083 and Diabetes. Biomedicines. 2024;12(4):924. doi:10.3390/biomedicines12040924
- 1084 Pirsaraei VA, Khodabandehloo H, Mousavi MA, Zhiani M, Nazari S, Fathi M. Association of
- 1085 RARRES2 rs17173608 gene polymorphism and serum Chemerin with acute myocardial
- 1086 infarction and its risk factors: A case-control study in an Iranian population. Gene.
- 1087 2024;900:148020. doi:10.1016/j.gene.2023.148020
- 1088 Dhingra R, Vasan RS. Biomarkers in Cardiovascular Disease. Trends Cardiovasc Med. 69.
- 1089 2017;27(2):123-133. doi:10.1016/j.tcm.2016.07.005
- 1090 Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting
- 1091 Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged
- 1092 Explanation and Elaboration. J Natl 2018;110(8):803-811. Cancer Inst.
- 1093 doi:10.1093/jnci/djy088
- 1094 Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease,
- 1095 and frailty. Nat Rev Cardiol. 2018;15(9):505-522. doi:10.1038/s41569-018-0064-2
- 1096 Yu HT, Park S, Shin EC, Lee WW. T cell senescence and cardiovascular diseases. Clin Exp
- 1097 Med. 2016;16(3):257-263. doi:10.1007/s10238-015-0376-z
- 1098 Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med.
- 2020;217(1):e20190459. doi:10.1084/jem.20190459 1099
- 1100 Serino A, Salazar G. Protective Role of Polyphenols against Vascular Inflammation, Aging

1101 and Cardiovascular Disease. Nutrients. 2018;11(1):53. doi:10.3390/nu11010053 1102 Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from 75. 1103 marvel Circulation. 2006;113(13):1708-1714. 1104 doi:10.1161/CIRCULATIONAHA.105.602532 1105 Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019;14(1):50-59. 1106 1107 doi:10.15420/ecr.2018.33.1 1108 Hattar L, Mumtaz T, El Mouhayyar C, Matevossian A, Johnstone M. The Effects and 1109 Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease. In: Johnstone 1110 M, Veves A, eds. Diabetes and Cardiovascular Disease. Springer International Publishing; 1111 2023:307-329. doi:10.1007/978-3-031-13177-6 10 1112 Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular 1113 Disease. Int J Mol Sci. 2022;23(21):12906. doi:10.3390/ijms232112906 1114 Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology. 2020;4:100130. doi:10.1016/j.ajpc.2020.100130 1115 1116 80. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute 1117 Coronary Syndrome. N Engl J Med. 2015;373(23):2247-2257. doi:10.1056/NEJMoa1509225 1118 Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium Glucose 1119 Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and 1120 Effects, Potential Mechanisms, and Clinical Applications. 1121 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887 1122 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The 1123 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major 1124 outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme 1125 inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering 1126 Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 1127 1128 Trombara F, Cosentino N, Bonomi A, et al. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction. Cardiovasc 1129 Diabetol. 2023;22(1):26. doi:10.1186/s12933-023-01758-y 1130 1131 De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled 1132 1133 trials. BMJ. 2009;339:b4531. doi:10.1136/bmj.b4531 1134 Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association 1135 1136 Diabetes Association. *Diabetes* the American *Care*. 2007;30(1):162-172.

1137 doi:10.2337/dc07-9917 1138 Authors/Task Force Members, Ryden L, Standl E, et al. Guidelines on diabetes, 1139 pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes 1140 and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the 1141 European Association for the Study of Diabetes (EASD). European Heart Journal. 2006;28(1):88-136. doi:10.1093/eurheartj/ehl260 1142 1143 87. Authors/Task Force Members, Rydén L, Grant PJ, et al. ESC Guidelines on diabetes, 1144 pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the 1145 Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society 1146 of Cardiology (ESC) and developed in collaboration with the European Association for the 1147 Study Diabetes (EASD). Heart J. 2013;34(39):3035-3087. Eur doi:10.1093/eurheartj/eht108 1148 1149 Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 1150 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486 1151 1152 Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of 1153 dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 1154 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 1155 Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 1156 1157 2024;149(8):e347-e913. doi:10.1161/CIR.000000000001209 1158 Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United 1159 States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS 1160 Med. 2009;6(4):e1000058. doi:10.1371/journal.pmed.1000058 Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of 1161 1162 cardiovascular events: potential mediating mechanisms. Circulation. 1163 2007;116(19):2110-2118. doi:10.1161/CIRCULATIONAHA.107.729939 Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. 1164 Oxid Med Cell Longev. 2009;2(5):270-278. doi:10.4161/oxim.2.5.9498 1165 1166 Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world 1167 diabetes prevention programs: learnings from the last 15 years. Implementation Sci. 2015;10(1):1-17. doi:10.1186/s13012-015-0354-6 1168 1169 D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in 1170 primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. 1171 doi:10.1161/CIRCULATIONAHA.107.699579 1172 Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk

study. BMJ. 2017;357:j2099. doi:10.1136/bmj.j2099

1173 1174 prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort

1175 Peng Y, Wang P, Gong J, et al. Association between the Finnish Diabetes Risk Score and 1176 cancer in middle-aged and older adults: Involvement of inflammation. Metabolism. 1177 2023;144:155586. doi:10.1016/j.metabol.2023.155586 1178 Jiang W, Siddiqui S, Barnes S, et al. Readmission Risk Trajectories for Patients With Heart 1179 Failure Using a Dynamic Prediction Approach: Retrospective Study. JMIR Med Inform. 1180 2019;7(4):e14756. doi:10.2196/14756 1181 Michael Yapanis, Steven James, Maria E Craig, David O'Neal, Elif I Ekinci. Complications of 99. 1182 Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose 1183 Monitoring. Clin Endocrinol Metab. 2022;107(6):e2221-e2236. doi:10.1210/clinem/dgac034 1184 1185 100. Gershuni VM, Yan SL, Medici V. Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr Nutr Rep. 2018;7(3):97-106. doi:10.1007/s13668-018-0235-0 1186 101. Ajoolabady A, Chiong M, Lavandero S, Klionsky DJ, Ren J. Mitophagy in cardiovascular 1187 1188 diseases: molecular mechanisms, pathogenesis, and treatment. Trends Mol Med. 1189 2022;28(10):836-849. doi:10.1016/j.molmed.2022.06.007 1190 102. Shi Y, Zhang H, Huang S, et al. Epigenetic regulation in cardiovascular disease: mechanisms 1191 and advances in clinical trials. Signal Transduct Target Ther. 2022;7(1):200. 1192 doi:10.1038/s41392-022-01055-2 1193 103. González N, Moreno-Villegas Z, González-Bris A, Egido J, Lorenzo Ó. Regulation of visceral 1194 and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity 1195 and diabetes. Cardiovascular Diabetology. 2017;16(1):44. doi:10.1186/s12933-017-0528-4 1196 104. Crea F. Heart failure and ischaemic heart disease: new challenges and opportunities. Eur 1197 Heart J. 2024;45(30):2681-2685. doi:10.1093/eurheartj/ehae497 1198 105. Balan Al, Halatiu VB, Scridon A. Oxidative Stress, Inflammation, and Mitochondrial Dysfunction: A Link between Obesity and Atrial Fibrillation. Antioxidants (Basel). 1199 1200 2024;13(1):117. doi:10.3390/antiox13010117 1201 106. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and 1202 Mortality Diabetes. Ν Engl J Med. 2015;373(22):2117-2128. in Type 2 1203 doi:10.1056/NEJMoa1504720 107. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in 1204 1205 Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827 1206 108. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. 1207

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221 1222

1223

1224

1225

1226

1227

1228

1229 1230

1231

1232

1233

1234

1235

1236

1237 1238

1239

1240

1241

1242

1243

doi:10.1056/NEJMoa2206286 109. Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74. doi:10.1186/s12933-022-01516-6 110. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172-1180. doi:10.1093/eurheartj/ehx566 111. Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular Diabetol 2019;11:80. diseases. Metab Syndr. doi:10.1186/s13098-019-0476-0 112. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034 113. Lahey R, Khan SS. Trends in Obesity and Risk of Cardiovascular Disease. Curr Epidemiol Rep. 2018;5(3):243-251. doi:10.1007/s40471-018-0160-1 114. Margaret Whillier, Jane Musial, Helen L. MacLaughlin. Evaluation of patient experience post structured education for diabetes self management (Dose Adjustment For Normal Eating-OzDAFNE). Diabetes Research Clinical Practice. and 2021;181. doi:10.1016/j.diabres.2021.109065 115. Heejin Jin, Ye An Kim, Young Lee, et al. Identification of genetic variants associated with diabetic kidney disease in multiple Korean cohorts via a genome-wide association study mega-analysis. BMC Medicine. 2023;21(1):16. doi:10.1186/s12916-022-02723-4 116. Foster D, Sanchez-Collins S, Cheskin LJ. Multidisciplinary Team-Based Obesity Treatment in Patients With Diabetes: Current Practices and the State of the Science. Diabetes Spectr. 2017;30(4):244-249. doi:10.2337/ds17-0045 117. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128 118. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368 119. Murtaza G, Virk HUH, Khalid M, et al. Diabetic cardiomyopathy - A comprehensive updated

1244 review. Prog Cardiovasc Dis. 2019;62(4):315-326. doi:10.1016/j.pcad.2019.03.003 1245 120. Dunlay SM, Roger VL. Understanding the Epidemic of Heart Failure: Past, Present, and 1246 Future. Curr Heart Fail Rep. 2014;11(4):404-415. doi:10.1007/s11897-014-0220-x 1247 121. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin 1248 in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 1249 122. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes 1250 with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and 1251 meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. 1252 doi:10.1016/S2213-8587(21)00203-5 1253 123. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24):2145-2153. doi:10.1016/j.jacc.2011.10.910 1254 1255 124. Tomov ML, Gil CJ, Cetnar A, et al. Engineering Functional Cardiac Tissues for Regenerative 1256 Medicine Applications. Curr Cardiol Rep. 2019;21(9):105. doi:10.1007/s11886-019-1178-9 125. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 1257 1258 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2 1259 126. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the 1260 United States: a policy statement from the American Heart Association. Circ Heart Fail. 1261 2013;6(3):606-619. doi:10.1161/HHF.0b013e318291329a 1262 127. Boehmer TK. Association Between COVID-19 and Myocarditis Using Hospital-Based 1263 Administrative Data — United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7035e5 1264 128. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level 1265 diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 1266 1267 2022;183:109119. doi:10.1016/j.diabres.2021.109119 1268 129. Zhou B, Bentham J, Cesare MD, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million 1269 1270 participants. The Lancet. 2017;389(10064):37-55. doi:10.1016/S0140-6736(16)31919-5 1271 130. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis 1272 1273 for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736-1788. 1274 doi:10.1016/S0140-6736(18)32203-7 131. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting 1275 1276 glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862 1277

Tables

TABLE 1. TOP 10 jorunals with publication volume from 2005 to May 2024

NO	Publication Titles	Counts	Percentage (%)	H-index	IF (2022)	Publishers
1	Plos One	199	3.615	435	3.7	Public Library Science
	International					
2	Journal Of	150	2.888	260	<i>5</i> (MDPI
2	Molecular	159		269	5.6	
	Sciences					
2	Cardiovascular	133	2.416	100	9.3	ВМС
3	Diabetology			108		
4	Nutrients	132	2.398	209	5.9	MDPI
5	Circulation	128	2.325	(71	37.8	Lippincott Williams &
3				674		Wilkins
6	Scientific Reports	85	1.544	315	4.6	Nature Portfolio
7	Bmc Public Health	83	1.508	197	4.5	BMC
	Frontiers In					
8	Cardiovascular	75	1.362	69	3.6	Frontiers Media SA
	Medicine					Frontiers Media SA
0	Frontiers In	75	1.362	120	5.2	
9	Endocrinology	13		120		Frontiers Media SA
10	Molecules	75	1.362	227	4.6	MDPI

TABLE 2. Top 25 authors in the filed of CVD in Diabetes from 2005 to 2024

NO.	Authors	Counts	Percentage (%)	Affiliations, Counties/Religious
1	Hu Frank	23	0.418	Harvard T.H. Chan School of Public Health , USA
2	Eliasson Björn	21	0.381	University of Gothenburg, Sweden
3	Mozaffarian Dariush	18	0.327	Tufts University, USA
4	Rimm Eric B.	17	0.309	Harvard T.H. Chan School of Public Health, USA
5	Schulze Matthias B	16	0.291	German Institute of Human Nutrition Potsdam-Rehbruecke , Germany
6	Shimomura Iichiro	15	0.272	Osaka University, Japan
7	Eeg-Olofsson Katarina	15	0.272	Sahlgrenska Academy, Sweden
8	Watada Hirotaka	14	0.254	Juntendo University, Japan
9	Zethelius Bjorn	14	0.254	Medical Products Agency, Sweden
10	Manson JoAnn E.	13	0.236	Harvard Medical School, USA
11	Khunti Kamlesh	13	0.236	University of Leicester College of Life Sciences, UK
12	Cederholm Jan	13	0.236	Uppsala universitet Disciplinary Domain of Medicine and Pharmacy, Sweden
13	Kengne Andre Pascal	13	0.236	Walter Sisulu University, South Africa
14	Azizi Fereidoun	13	0.236	University of Oklahoma System, USA
15	Sattar Naveed	12	0.218	University of Glasgow, UK
16	Mita Tomoya	12	0.218	Juntendo University , Japan
17	Woodward Mark	12	0.218	University of New South Wales Sydney, Australia
18	Svensson Ann-Marie	12	0.218	University of Gothenburg, Sweden
19	Guo yu	12	0.218	Kangwon National University, South Korea
20	Li Li	12	0.218	Chinese Academy of Medical Sciences - Peking Union Medical College, China
21	Gudbjornsdottir Soffia	12	0.218	Ctr Registers Reg Vastra Gotaland, Sweden
22	Lam Cindy Lo Kuen	11	0.200	University of Hong Kong, China
23	Stehouwer Coen	11	0.200	Maastricht University Medical Centre , Netherlands
24	Ezzati Majid	11	0.200	Imperial College London, UK
25	Peters Annette	11	0.200	Helmholtz-Center Munich - German Research Center for Environmental Health, Germany

TABLE 3. Top 10 references with the strongest citation bursts in the DM+CVD field (2021-2024)

NO.	References	Year	Strength	Begin	End	2021 -2024
	Zinman B, 2016, NEW ENGL J MED,					
1	Empagliflozin, Cardiovascular Outcomes, and	2016	10.14	2022	2024	
	Mortality in Type 2 Diabetes					
	Powell-Wiley TM, 2021, CIRCULATION, V143,					
2	PE984, Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart		9.37	2021	2022	_
2						
	Association					
	Marso SP, 2016, NEW ENGL J MED, V375, P311,					
3	Liraglutide and Cardiovascular Outcomes in Type 2	2016	9.12	2022	2024	
	Diabetes					
	Sun H, 2022, DIABETES RES CLIN PR, V183, P0,					
4	IDF Diabetes Atlas: Global, regional and	2022	7.00	2022	2022	
4	country-level diabetes prevalence estimates for 2021	2022	7.23	2022	2022	-
	and projections for 2045					
	McDonagh TA, 2021, EUR HEART J, V42, P3599,					
5	2021 ESC Guidelines for the diagnosis and treatment	2021	6.81	2021	2022	
	of acute and chronic heart failure					
	Heerspink HJL, 2016, CIRCULATION, V134,					
	P752,Sodium Glucose Cotransporter 2 Inhibitors in					
6	the Treatment of Diabetes Mellitus: Cardiovascular	2016	5.56	2022	2024	
	and Kidney Effects, Potential Mechanisms, and					
	Clinical Applications					
	Mach F, 2019, ATHEROSCLEROSIS, V290, P140,					
	2019 ESC/EAS Guidelines for the management of	2019				
7	dyslipidaemias: lipid modification to reduce		5.52	2021	2022	
	cardiovascular risk					
	Solomon SD, 2022, NEW ENGL J MED, V0,					
8	P0,Dapagliflozin in Heart Failure with Mildly	2022	5.1	2022	2022	_
	Reduced or Preserved Ejection Fraction					•
	Ponikowski P, 2016, EUR HEART J, V37, P2129,					
	2016 ESC Guidelines for the diagnosis and treatment					
	of acute and chronic heart failure: The Task Force for					
9	the diagnosis and treatment of acute and chronic heart	2016	5.05	2022	2024	
	failure of the European Society of Cardiology			*= =		
	(ESC)Developed with the special contribution of the					
	Heart Failure Association (HFA) of the ESC					
	110 11 11 11 11 11 11 11 11 11 11 11 11					

Murtaza G, 2019, PROG CARDIOVASC DIS, V62,

Supplementary Table

1324

Table S1. Thematic Areas for Meso-level Citation Analysis

NO.	Citation topics Meso
1	Diabetes
2	Phytochemicals
3	Lipids
4	Nutrition & Dietetics
5	Cardiology - Circulation
6	Cardiology - General
7	Healthcare Policy
8	Molecular & Cell Biology - Cancer
9	Autophagy & Apoptosis
10	Sleep Science & Circadian Systems
11	Molecular & Cell Biology - Pharmacology
12	Micro & Long Noncoding Rna
13	Obstetrics & Gynecology
14	Genome Studies
15	Immunology
16	Nursing
17	Psychiatry
18	Stem Cell Research
19	Molecular & Cell Biology - Mitochondria
20	Cardiac Arrhythmia
21	Strokes
22	Auto-inflammatory Diseases
23	Extracellular Matrix & Cell Differentiation
24	Vascular
25	Cardiac & Thoracic Surgery
26	Molecular & Cell Biology - Genetics
27	Molecular & Cell Biology - Physiology
28	Substance Abuse
29	Endocrinology & Metabolism
30	Smoking Cessation
31	Health Literacy & Telemedicine
32	Antibiotics & Antimicrobials
33	Social Psychology
34	Hematologic Diseases




FIG.1





FIG.2








FIG.4






FIG.5

Top 25 Keywords with the Strongest Citation Bursts


fiabetic cardiomyopathy 2018 20.01 2021 2024 2016 2016 2019 2022 18.54 2022 2024 2024 2024 2024 2024 2024 20	Keywords	Year S	trength Begin End	2005 - 2024
pidemiology 2022 18.54 2022 2024 scute myocardial infarction 2005 18.18 2005 2012 nechanism 2007 16.14 2022 2024 nitric oxide synthase 2006 13.26 2006 2015 neart failure 2007 12.98 2021 2024 nancer 2011 11.82 2018 2021 2024 nancer 2015 11.12 2018 2019 neart 2015 11.12 2018 2019 neart 2015 11.12 2018 2019 neart 2015 11.06 2007 2016 nancer 2016 10.41 2019 2020 nardiovascular risk 2006 10.41 2019 2020 nardiovascular risk 2006 10.16 2021 2022 nardiovascular risk 2006 10.16 2021 2022 nardiovascular risk 2016 10.16 2021 2022 nardiovascular risk factor 2007 9.51 2013 2014 nardiovascular risk factor 2007 9.51 2013 2019 nardiovascular risk factor 2007 9.51 2013 2015	c reactive protein	2005	20.22 2005 2014	
pridemiology 2022 18.54 2022 2024 scute myocardial infarction 2005 18.18 2005 2012 mechanism 2007 16.14 2022 2024 no vitro 2009 15.65 2020 2022 nitric oxide synthase 2006 13.26 2006 2015 mpaired glucose tolerance 2005 13.18 2005 2013 neart failure 2007 12.98 2021 2024 cancer 2011 11.82 2018 2021 2024 care 2008 11.36 2019 2021 care 2008 11.36 2016 2018 neart 2015 11.12 2018 2019 neart 2015 11.12 2018 2019 neart 2015 11.06 2007 2016 neart 2016 2018 cardiovascular risk 2006 10.41 2019 2020 cardiovascular risk 2006 10.16 2021 2022 cardiovascular risk 2006 9.98 2006 2013 mooth muscle cell 2006 9.98 2006 2013 mooth muscle cell 2006 9.64 2006 2016 cardiovascular risk factor 2007 9.51 2013 2014 nima media thickness 2006 9.44 2018 2019 nearpy 2012 9.41 2012 2015	diabetic cardiomyopathy	2018	20.01 2021 2024	
scute myocardial infarction 2005 18.18 2005 2012 16.14 2022 2024 17.14 2022 2024 17.15 2009 15.65 2020 2022 17.15 2009 15.65 2020 2022 17.15 2009 15.65 2020 2022 17.15 2009 13.26 2006 2015 17.18 2006 2015 17.18 2018 2021 2024 17.18 2018 2021 2024 17.18 2018 2021 2024 17.18 2018 2021 2024 2021 2024 2021 2024 2021 2024 2021 2021	follow up	2005	19.24 2005 2014	
nechanism 2007 16.14 2022 2024 n vitro 2009 15.65 2020 2022 itric oxide synthase 2006 13.26 2006 2015 mpaired glucose tolerance 2005 13.18 2005 2013 neart failure 2007 12.98 2021 2024 ancer 2011 11.82 2018 2021 double blind 2019 11.46 2019 2021 are 2008 11.36 2016 2018 neart 2015 11.12 2018 2019 nen 2005 11.06 2007 2016 nen 2005 11.06 2007 2016 ardiovascular risk 2006 10.41 2019 2020 ardiovascular risk 2006 10.16 2021 2022 activated protein kinase 2012 10.1 2012 2017 ardiovascular risk factor 2007 9.51 2013 2014 ardiovascular risk factor 2007 9.51 2013 2014 ardiovascular risk factor 2007 9.51 2013 2019 herapy 2012 9.41 2012 2015 herapy 2012 9.41 2012 2015	epidemiology	2022	18.54 2022 2024	
n vitro 2009 15.65 2020 2022	acute myocardial infarctio	n 2005	18.182005 2012	
itric oxide synthase 2006 13.26 2006 2015	mechanism	2007	16.142022 2024	
mpaired glucose tolerance 2005 13.18.2005 2013 neart failure 2007 12.98.2021 2024 rancer 2011 11.82.2018 2021 double blind 2019 11.46.2019 2021 rare 2008 11.36.2016 2018 neart 2015 11.12.2018 2019 nen 2005 11.06.2007 2016 nen 2006 10.41.2019 2020 rardiovascular risk 2006 10.41.2019 2020 scrivated protein kinase 2012 10.1.2012 2017 ow density lipoprotein 2006 9.98.2006 2013 rmooth muscle cell 2006 9.64.2006 2016 rardiovascular risk factor 2007 9.51.2013 2014 ntima media thickness 2006 9.44.2018 2019 herapy 2012 9.41.2012 2015	in vitro	2009	15.65 2020 2022	
reart failure 2007 12.98 2021 2024 2021 2021 2021 2021 2021 2021	nitric oxide synthase	2006	13.262006 2015	
reart failure 2007 12.98 2021 2024 2021 2021 2021 2021 2021 2021	impaired glucose tolerano	e 2005	13.182005 2013	
double blind 2019 11.46 2019 2021 2018 2019 2015 11.12 2018 2019 2015 11.06 2007 2016 2018 2019 2016 2018 2019 2016 2018 2019 2016 2016 2018 2019 2016 2018 2019 2016 2018 2019 2018 2019 2018 2018 2018 2018 2018 2018 2018 2018	heart failure	2007		
tare 2008 11.36 2016 2018 11.12 2018 2019 11.06 2007 2016 11.06 2007 2016 11.06 2007 2016 11.06 2007 2016 11.06 2007 2016 11.06 2018 2020 2016 10.41 2019 2020 2016 2016 2016 2016 2016 2016 2016	cancer	2011	11.82 2018 2021	
nen 2005 11.06 2007 2016	double blind	2019	11.46 2019 2021	
nen 2005 11.06 2007 2016 10.46 2018 2020 10.46 2018 2020 10.41 2019 2020 10.41 2019 2020 10.16 2021 2022 10.16 2021 2022 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2017 10.16 2021 2016 10.16 2021 2022 2022 2022 2022 2022 2022 20	care	2008	11.362016 2018	
ardiovascular risk 2006 10.41 2019 2020 ardiovascular risk 2006 10.16 2021 2022 ardiovascular risk 2016 10.16 2021 2022 ardiovascular risk 2012 10.1 2012 2017 2017 2018 2019 2019 2019 2019 2019 2019 2019 2019	heart	2015	11.12 2018 2019	_
ardiovascular risk 2006 10.41 2019 2020	men	2005	11.06 2007 2016	
thronic kidney disease 2016 10.16 2021 2022 2017 2012 2017 2018 2018 2019 2018 2019 2018 2018 2018 2018 2018 2018 2018 2018	all cause mortality	2014	10.462018 2020	
ow density lipoprotein 2006 9.98 2006 2013 000 density lipoprotein 2006 9.98 2006 2013 000 000 density lipoprotein 2006 9.64 2006 2016 000 000 density lipoprotein 2006 9.64 2006 2016 000 000 000 000 000 000 000 000 000	cardiovascular risk	2006	10.41 2019 2020	
ow density lipoprotein 2006 9.98 2006 2013	chronic kidney disease	2016	10.162021 2022	
mooth muscle cell 2006 9.64 2006 2016 ardiovascular risk factor 2007 9.51 2013 2014 ntima media thickness 2006 9.44 2018 2019 herapy 2012 9.41 2012 2015	activated protein kinase	2012	10.1 2012 2017	
mooth muscle cell 2006 9.64 2006 2016 ardiovascular risk factor 2007 9.51 2013 2014 ntima media thickness 2006 9.44 2018 2019 herapy 2012 9.41 2012 2015	low density lipoprotein	2006	9.98 2006 2013	
rardiovascular risk factor 2007 9.51 2013 2014	smooth muscle cell	2006		
ntima media thickness 2006 9.442018 2019 herapy 2012 9.412012 2015	cardiovascular risk factor	2007		
herapy 2012 9.41 2012 2015	intima media thickness	2006		
overweight 2008 8.77 2020 2021	therapy	2012		
	overweight	2008	8.77 2020 2021	







Citelipace, v. 6.3.81 (84-bit) Advanced
July 15, 2024, 5:35:35 PM CG17
Wildis C-Maren Museum Density OSC Cristia
Timosia C-Maren Museum Density OSC Cristia
Retearch X-77, 6-770 (Density OSC Maren Density OSC



Clarifiguro, v. 6.3.81 (64-36) Advanced July 16, 1283, v. 122.05 (Pt Clarific Clarif

